Michael Makris Shares an Update on The Safety of Andexxa
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared on LinkedIn:
”Andexxa (andexanet alfa), the only specific anti-Xa reversal agent, has been withdrawn from the US market on December 22, 2025.
It was marketed for the reversal of Rivaroxaban and Apixaban.
The theory was great, but it was very expensive and had a higher thrombotic risk than when PCC was used for reversal.
Below is the announcement on the FDA website.
As far as I know, it is still being sold and used in Europe, but I can not see this continuing.
There is nothing on the EMA website.
Also, rather surprisingly, there is no mention of this on the AstraZeneca US or UK websites about this.
Do their medical communication teams not work in the second part of December?”
Read the full announcement here.
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 12, 2026, 06:12Precision in Antithrombotic Therapy at ISTH 2026 – The Lancet Haematology
-
Jul 11, 2026, 23:36Emmanuel J Favaloro: A Fresh Perspective on the Manual Tilt Tube Method for PT and INR Determination
-
Jul 11, 2026, 21:44Timos Papagatsias: From Promising Concepts to Clinical Differentiation at ISTH 2026
-
Jul 11, 2026, 21:43Sharing New Research in Hemophilia at ISTH 2026 – Novo Nordisk Medical US
-
Jul 11, 2026, 21:41Bianca Constantin: Don’t Miss the ISTH Early Career Committee Activities
-
Jul 11, 2026, 21:38Fateme Babaha: Don’t Miss Your Favorite ISTH 2026 Sessions
-
Jul 11, 2026, 21:11Farjah Algahtani: Learning, Sharing, and Collaborating at ISTH 2026
-
Jul 11, 2026, 19:56Louise St. Germain Bannon: A Fantastic Start to ISTH 2026 and the Future of Thrombosis Research
-
Jul 11, 2026, 19:38Lynn Kloeckner: Recognizing Kirsten Lacine’s Impact on the Stroke Survivor Journey